Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Ohio State University Comprehensive Cancer Center
Novelty Nobility, Inc.
Merck Sharp & Dohme LLC
Sichuan Baili Pharmaceutical Co., Ltd.
Hutchmed
23andMe, Inc.
Tarveda Therapeutics
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
University of Maryland, Baltimore
Stanford University